THE global leader in  blood management solutions for our customers

2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
Nov. 18, 2016The Medical Center of Plano Texas Selects Haemonetics® BloodTrack® Technology
Hospital joins several healthcare organizations that use the innovative technology to deliver life-saving blood transfusions to trauma patients BRAINTREE, Mass., Nov. 18, 2016 /PRNewswire/ -- Haemonetics®, a healthcare technology provider dedicated to delivering innovative products and solutions to healthcare organizations around the world, today announced it deployed its BloodTrack® Emerge® software at The Medical Center of Plano. Joining several leading healthcare institutions in th... 
Printer Friendly Version
Nov. 07, 2016Haemonetics 2nd Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
Financial release accessible online BRAINTREE, Mass., Nov. 7, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that second quarter and first half fiscal year 2017 financial results are available on its Investor relations website. The Company is posting this press release and additional commentary entitled Comments on 2nd Quarter and First Half Fiscal 2017 Results to its Investor Relations website.  Direct link to Earnings Release FY17 Q2:   http://phx.corp... 
Printer Friendly Version
Oct. 27, 2016Catherine M. Burzik Joins Haemonetics Board of Directors
BRAINTREE, Mass., Oct. 27, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced the election of Catherine M. Burzik, a highly respected and accomplished senior executive in the healthcare industry, to its Board of Directors. Ms. Burzik successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Richard J. Meelia, Chairman of Haemonetics' Board of Directors commented, "Cathy Burzik brings extensive experience as a superb operator and a hi... 
Printer Friendly Version
Oct. 13, 2016Haemonetics Sets Date for 2nd Quarter Fiscal 2017 Earnings Release: November 7, 2016
BRAINTREE, Mass., Oct. 13, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that the Company will publish fiscal year 2017 second quarter financial results at 6:00am Eastern Time on Monday, November 7, 2016. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on November 7, 2016.  Webcast Link: http://edge.media-server.com/m/p/wcn22ipf Webcast replay will be available f... 
Printer Friendly Version
Aug. 31, 2016Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
BRAINTREE, Mass., Aug. 31, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on Monday, September 12, 2016 at 1:40pm Eastern time. The public may access Mr. Simon's presentation live via webcast at: https://cc.talkpoint.com/morg007/091216a_ae/?entity=108_F0B4KMD. About Haemonetics Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing... 
Printer Friendly Version
Aug. 29, 2016Haemonetics to Present at The Baird 2016 Global Healthcare Conference
BRAINTREE, Mass., Aug. 29, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Gerry Gould, Vice President – Investor Relations, will present at The Baird 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 3:10pm Eastern time. The public may access Mr. Gould's presentation live via webcast at http://wsw.com/webcast/baird46/hae. ABOUT HAEMONETICS Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of inno... 
Printer Friendly Version
Aug. 08, 2016Haemonetics CEO Completes Open Market Share Purchase
BRAINTREE, Mass., Aug. 8, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that Christopher Simon, President and CEO, has acquired 60,000 shares of the Company's common stock at an average price per share of $35.00. The acquisition of these shares was by open market purchases taking place during the last three business days. Mr. Simon joined the Company as Chief Executive Officer effective May 16, 2016. Under the terms of his compensation agreement, the Company will ... 
Printer Friendly Version
Aug. 01, 2016Haemonetics Appoints Bill Burke CFO
BRAINTREE, Mass., Aug. 1, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions. Mr. Burke will join the Company directly from Medtronic, Inc. where he has served as Chief Integration Officer for the integration of Covidien... 
Printer Friendly Version
Aug. 01, 2016Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website
Financial release accessible online   BRAINTREE, Mass., Aug. 1, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.   The Company is posting this press release and additional commentary to be discussed on the webcast entitled Comments on 1st Quarter Fiscal 2017 Results to its Investor Relations website.    Direct link to Earnings Release FY17 Q1: http://phx.corporate... 
Printer Friendly Version
Jul. 18, 2016Haemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016
BRAINTREE, Mass., July 18, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that the Company will publish fiscal year 2017 first quarter financial results at 6:00am Eastern Time on Monday, August 1, 2016. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on August 1, 2016.  Webcast Link: http://edge.media-server.com/m/p/vnuvfpge Webcast replay will be available from... 
Printer Friendly Version
Jun. 01, 2016Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s
New hemostasis analysis system allows clinicians to better maintain a patient's coagulation equilibrium using unique all-in-one design.San Diego, CA & Braintree, MA (June 1) 2016 – Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, ... 
Printer Friendly Version
May. 26, 2016Haemonetics to Present at Jefferies 2016 Healthcare Conference
BRAINTREE, Mass., May 26, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President – Investor Relations, will present at the Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 1:30pm Eastern time.  The public may access Mr. Gould's presentation live via webcast at http://wsw.com/webcast/jeff97/hae. ABOUT HAEMONETICS Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative solutio... 
Printer Friendly Version
May. 09, 2016Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer
BRAINTREE, Mass., May 9, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products Practice, will assume his duties on May 16, 2016. "With over twenty years of experience consult... 
Printer Friendly Version
May. 09, 2016Haemonetics Provides Fiscal 2017 Guidance
BRAINTREE, Mass., May 9, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) provided guidance for its fiscal year ending April 1, 2017. The Company follows a fiscal year reporting convention, ending on the Saturday closest to March 31. Under this reporting convention, fiscal 2016 had 53 weeks and fiscal 2017 will have 52 weeks. The extra week in fiscal 2016 provided approximately 1.7% of revenue. REVENUE Overall fiscal 2017 revenue is expected to be in a range of $850-$875 mill... 
Printer Friendly Version
May. 02, 2016Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported
BRAINTREE, Mass., May 2, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%.  Revenue was up 10% over the fourth quarter of fiscal 2015 in constant currency, benefiting by 6.8% from the inclusion of a 53rd week.  The Company reported a GAAP net loss of $8.8 million or $0.17 per share in the fourth quarter of fiscal 2016. Exclusive of non-cash asset impairments, transformation, restructuring and deal amortization exp... 
Printer Friendly Version
Apr. 29, 2016Haemonetics Honored for Delivering 'World-Class' Customer Service
Receives Omega's prestigious NorthFace ScoreBoard Award(SM) for exceeding customer expectations BRAINTREE, Mass., April 29, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that it has received the NorthFace ScoreBoard AwardSM from Omega Management Group Corp. in recognition of achieving excellence in customer service and support in 2015. This marks the sixteenth consecutive year that Haemonetics has earned this high honor. Since 2000, the award has been presented annu... 
Printer Friendly Version
Apr. 14, 2016Haemonetics Announces CFO's Retirement
BRAINTREE, Mass., April 14, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development has announced his retirement from Haemonetics Corporation effective May 27, 2016.  The Company announced it will immediately begin a search for Mr. Lindop's successor. Mr. Lindop joined the Company in 2007 and has led the Company's finance, investor relations and business development activitie... 
Printer Friendly Version
Apr. 07, 2016Haemonetics Sets Date for 4th Quarter and Fiscal 2016 Earnings Release: May 2, 2016
BRAINTREE, Mass., April 7, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company will report its results for the fourth quarter and fiscal year 2016 on Monday, May 2, 2016 in a pre-market press release. As previously announced, the Company will provide its outlook for fiscal 2017 as part of a comprehensive review of its business franchise strategies at its annual investor day event on May 10, 2016. The Company will hold a webcast conference call with investors... 
Printer Friendly Version
Apr. 05, 2016Haemonetics Sets Date for Investor/Analyst Meeting - May 10, 2016
BRAINTREE, Mass., April 5, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that it will host its annual investor and analyst meeting on Tuesday, May 10th from 9:00am to 2:30pm at The State Room, 60 State Street in Boston, Massachusetts. The agenda for the meeting will include results of the Company's strategic review of its business franchise opportunities, fiscal 2017 guidance and longer-range financial indications. The meeting is open to analysts, shareholders,... 
Printer Friendly Version
Mar. 02, 2016Haemonetics to Present at the Raymond James 37th Annual Institutional Investors Conference
BRAINTREE, Mass., March 2, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President – Investor Relations, will present at the Raymond James 37th Annual Institutional Investors Conference in Orlando, FL on Wednesday, March 9, 2016 at 7:30 am Eastern time.  The public may access Mr. Gould's presentation live via webcast at http://wsw.com/webcast/rj99/hae. Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative... 
Printer Friendly Version
Feb. 01, 2016Haemonetics Reports 3rd Quarter Fiscal 2016 Revenue of $233 Million, Constant Currency Revenue Growth of 4% and 1% As Reported
BRAINTREE, Mass., Feb. 1, 2016 /PRNewswire/ -- Revenue Growth Highlights The constant currency revenue increase in the third quarter included strong performance from identified growth drivers: 14% growth in Plasma disposables revenue 18% growth in Hemostasis Management (TEG®) disposables revenue 9% growth in Emerging Markets disposables revenue, ex-Russia Haemonetics Corporation (NYSE: HAE) reported third quarter fiscal 2016 revenue of $233.4 million, up 1%.  Revenue was up ... 
Printer Friendly Version
Jan. 07, 2016Haemonetics Sets Date for 3rd Quarter Fiscal 2016 Earnings Release: February 1, 2016
BRAINTREE, Mass., Jan. 7, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that the Company will report its results for the third quarter of fiscal year 2016 on Monday, February 1, 2016 in a pre-market press release.  The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00 am Eastern Time on February 1, 2016.  Webcast Link: http://edge.media-server.com/m/p/mieb5m8u Webcast replay will ... 
Printer Friendly Version